tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MedPlus Subsidiary Faces Temporary Drug License Suspension in Telangana

Story Highlights
  • MedPlus subsidiary received a three-day suspension for a store’s Drug License in Telangana.
  • The suspension may lead to a potential revenue loss of approximately Rs 1.73 lacs.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
MedPlus Subsidiary Faces Temporary Drug License Suspension in Telangana

TipRanks Cyber Monday Sale

MedPlus Health Services Ltd. ( (IN:MEDPLUS) ) has shared an announcement.

MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a Drug License at a store in Telangana. The suspension, issued under the Drugs and Cosmetics Act, 1940, will last for three days and is expected to result in a potential revenue loss of approximately Rs 1.73 lacs. This incident highlights regulatory compliance challenges that could impact the company’s operations and financial performance.

More about MedPlus Health Services Ltd.

MedPlus Health Services Ltd. operates in the healthcare industry, primarily focusing on providing pharmaceutical products and health services through its retail pharmacy chain. The company is headquartered in Hyderabad, India, and has a significant presence in the Indian market.

Average Trading Volume: 28,774

Technical Sentiment Signal: Hold

Current Market Cap: 94.36B INR

See more data about MEDPLUS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1